Samuel Martin Biography and Net Worth

CFO of Celldex Therapeutics

Mr. Martin joined Celldex in April 2009 as Director of Financial Reporting, Planning and Analysis and most recently served as Vice President, Finance. Prior to joining Celldex, Mr. Martin served as the Director of Finance and Corporate Compliance for Alseres Pharmaceuticals, where he was responsible for managing the financial and SEC reporting and the annual budget and planning process. Mr. Martin began his career at Ernst & Young, holding various positions prior to completing his tenure as Audit Manager, where he provided audit, review, due diligence and consulting services to public and private companies in the biotechnology, medical device, health care, high technology, manufacturing and consumer product industries. Mr. Martin received an M.B.A. from Boston University, a B.S. from Skidmore College and is a Certified Public Accountant.

What is Samuel Bates Martin's net worth?: The estimated net worth of Samuel Bates Martin is at least $662,343.75 as of June 14th, 2024. Mr. Martin owns 28,125 shares of Celldex Therapeutics stock worth more than $662,344 as of November 16th. This net worth estimate does not reflect any other investments that Mr. Martin may own. Learn More about Samuel Bates Martin's net worth.
How do I contact Samuel Bates Martin?: The corporate mailing address for Mr. Martin and other Celldex Therapeutics executives is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. Celldex Therapeutics can also be reached via phone at (908) 454-7120 and via email at [email protected]. Learn More on Samuel Bates Martin's contact information.
Has Samuel Bates Martin been buying or selling shares of Celldex Therapeutics?: Samuel Bates Martin has not been actively trading shares of Celldex Therapeutics during the last ninety days. Most recently, Samuel Bates Martin sold 17,172 shares of the business's stock in a transaction on Friday, June 14th. The shares were sold at an average price of $35.42, for a transaction totalling $608,232.24. Following the completion of the sale, the chief financial officer now directly owns 28,125 shares of the company's stock, valued at $996,187.50. Learn More on Samuel Bates Martin's trading history.
Who are Celldex Therapeutics' active insiders?: Celldex Therapeutics' insider roster includes Sarah Cavanaugh (SVP), Elizabeth Crowley (VP), Freddy Jimenez (SVP), Samuel Martin (CFO), Anthonly Marucci (President & CEO), and Diane Young (SVP). Learn More on Celldex Therapeutics' active insiders.
Are insiders buying or selling shares of Celldex Therapeutics?: In the last year, Celldex Therapeutics insiders bought shares 1 times. They purchased a total of 11,500 shares worth more than $308,430.00. In the last year, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 266,332 shares worth more than $9,155,821.33. The most recent insider tranaction occured on November, 11th when CEO Anthony S Marucci bought 11,500 shares worth more than $308,430.00. Insiders at Celldex Therapeutics own 3.8% of the company. Learn More about insider trades at Celldex Therapeutics.
Information on this page was last updated on 11/11/2024.

Samuel Bates Martin Insider Trading History at Celldex Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/14/2024	Sell	17,172	$35.42	$608,232.24	28,125
5/30/2024	Sell	35,000	$34.05	$1,191,750.00	25,128
8/12/2022	Sell	17,547	$36.45	$639,588.15	24,378
12/23/2021	Sell	9,500	$42.00	$399,000.00
11/15/2021	Sell	9,500	$43.57	$413,915.00
8/10/2021	Sell	2,738	$45.25	$123,894.50
6/9/2020	Buy	9,750	$2.99	$29,152.50

Samuel Bates Martin Buying and Selling Activity at Celldex Therapeutics

Celldex Therapeutics Company Overview

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Today's Range

Now: $23.55

$23.49

$25.89

50 Day Range

MA: $31.89

$23.55

$44.16

2 Week Range

Now: $23.55

$23.49

$53.18

Volume

1,249,780 shs

Average Volume

1,057,140 shs

Market Capitalization

$1.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6

War on Elon Escalates…

From Porter & Company | Ad

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.